Results 191 to 200 of about 71,600 (239)

Effusion Reduction after Early Trastuzumab Deruxtecan Therapy for Unresectable HER2-Low Breast Cancer in an Older Patient: A Case Report. [PDF]

Surg Case Rep
Akabane A, Kawai M, Suzuki K, Goto A, Tanaka T, Futakuchi M, Motoi F.   +6 more
europepmc   +1 more source

The diagnostic implications of the pleural fluid cell differentiation. [PDF]

J Thorac Dis
Bansal K, Ee WW, Patole S, Medford A, Maskell N, Walker S, Arnold D.   +6 more
europepmc   +1 more source

Mapping heterogeneity in the management of malignant pleural effusions with indwelling pleural catheters in Denmark - a national survey. [PDF]

Eur Clin Respir J
Ali AKM, Fjaellegaard K, Laursen CB, Skaarup SH, Armbruster K, Bødtger U.   +5 more
europepmc   +1 more source

Diagnostic efficacy and subgroup heterogeneity of SHOX2, RASSF1A, Septin9, and HOXA9 methylation in pleural effusion lymphoma. [PDF]

Clin Epigenetics
Bo J, Lei Z, Zhang S, He M, Huang X, She B, Ren X, Li J, Wang S, Rui W, Zeng Y, Yi X.   +11 more
europepmc   +1 more source

Risk factors for refractory malignant pleural effusion and the impact on prognosis in non-small cell lung cancer patients with advanced EGFR mutations: a retrospective cohort study using propensity score matching. [PDF]

Transl Cancer Res
Lian HN, Shi GQ, Wang H, Wu ZY, Ma LJ, Xiao ZL, Zhou J.   +6 more
europepmc   +1 more source

The Diagnosis and Treatment of Lung Cancer: Methods, evidence and guidance [PDF]

, 2005
Belchamber, C.A., National Collaborating Centre for Acute Care,   +1 more
core  

Development of a scoring system based on a nomogram to identify malignant pleural effusion. [PDF]

J Thorac Dis
Li J, Hou H, Gao J.
europepmc   +1 more source

Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up [PDF]

, 2017
Felip, E., Stahel, R A., Weder, W.
core  

Post-lobectomy lung abscess. [PDF]

J Surg Case Rep
Kim SE, Steeno D, Qureshi HA, Lynch AP, Podbielski FJ.   +4 more
europepmc   +1 more source

EGFR p.V774M/p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC- and Furmonertinib-Based Treatment: A Case Report. [PDF]

Cancer Rep (Hoboken)
Wang Y, Ren G, Song Z, Hu L, Li W, Wang X.   +5 more
europepmc   +1 more source